207235-82-3

Basic information

• Product Name: 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-hydroxymethyl-2-phenylethyl]acetamide
• Synonyms: 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-hydroxymethyl-2-phenylethyl]acetamide
• CAS NO: 207235-82-3
• Molecular Weight: 530.556
• Mol File: 207235-82-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-hydroxymethyl-2-phenylethyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-hydroxymethyl-2-phenylethyl]acetamide(207235-82-3)
• EPA Substance Registry System: 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-hydroxymethyl-2-phenylethyl]acetamide(207235-82-3)

Safety Data

• Hazardous Substances Data: 207235-82-3(Hazardous Substances Data)

Upstream product

• 207234-95-5 2-[5-benzloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-[(2-benzoxazolyl)carbonyl]-2-phenylethyl]acetamide 
• 1795-98-8 rac-phenylalaninol 
• 148747-76-6 [5-[(benzyloxycarbonyl)amino]-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]acetic acid 

Downstream Products

• 207235-15-2 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[2-phenyl-1-[(2-thiazolyl)carbonyl]ethyl]acetamide 
• 207235-89-0 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[2-phenyl-1-[(2-thiazolyl)hydroxymethyl]ethyl]acetamide 
• 339209-10-8 2-[5-benzyloxycarbonylamino-2-(4-fluorophenyl)-6-oxo-1,6-dihydro-1-pyrimidinyl]-N-[1-formyl-2-phenylethyl]acetamide 

Relevant articles and documents

Synthesis, structure - Activity relationships, and pharmacokinetic profiles of nonpeptidic α-keto heterocycles as novel inhibitors of human chymase

We designed nonpeptidic chymase inhibitors based on the structure of a peptidic compound (1) and demonstrated that the combination of a pyrimidinone skeleton as a P3-P2 scaffold and heterocycles as P1 carbonyl-activating g